Fundamentals screen · refreshed after the Nov 12, 2026 close
Low P/E with growing sales: Healthcare
Profitable companies priced below 12× earnings whose revenue is still growing. Price-to-earnings uses trailing-twelve-month net income. Low multiples can signal value or a business the market expects to shrink — growing revenue helps separate the two.
| # | Company | Price | P/E | Revenue YoY | Net margin | Mkt cap |
|---|---|---|---|---|---|---|
| 1 | NVSTEnvista Holdings Corporation Common stock, $0.01 par value per shareHealthcare | $24.66 | 6.2× | +3.2% | 73.5% | $3.95B |
| 2 | AUPHAurinia PharmaceuticalsHealthcare | $16.21 | 6.9× | +13.9% | 37.9% | $2.17B |
| 3 | UHSUniversal Health ServicesHealthcare | $193.84 | 7.6× | +5.3% | 6.5% | $11.18B |
| 4 | ALNYAlnylam PharmaceuticalsHealthcare | $156.65 | 7.7× | +16.7% | 148.6% | $20.98B |
| 5 | THCTenet Healthcare Corporation NewHealthcare | $286.86 | 7.9× | +6.5% | 17.8% | $22.83B |
| 6 | ACADAcadia PharmaceuticalsHealthcare | $18.14 | 8.7× | +22.8% | 15.6% | $3.14B |
| 7 | AVAHAveanna Healthcare HoldingsHealthcare | $12.24 | 9.7× | +13.7% | 6.0% | $2.67B |
| 8 | BIOBio-Rad LaboratoriesHealthcare | $370.48 | 9.7× | +0.5% | 69.9% | $9.96B |
| 9 | BIO.BBio-Rad LaboratoriesHealthcare | $389.98 | 10.3× | +0.5% | 69.9% | $10.49B |
| 10 | DVADaVitaHealthcare | $174.07 | 11.9× | +3.3% | 6.5% | $10.95B |
Method & sources
Computed after each close from Massive / Polygon prices (split-adjusted), SEC filings, FINRA short-interest settlements and FMP earnings dates. Rows are rebuilt every session; a stock appears only when every criterion is met with current data. Full methodology
Informational screen, not a recommendation.